Moreover, AR inhibition can activate Akt signaling by reducing levels of AKT phosphatase PHLPP in prostate PTEN-deficient murine prostate cancer model and in human prostate cancer xenografts (Carver et al., 2011). Here, AR is linked to prostate carcinoma.